CD36, a fatty acid transporter enzyme in the liver, is linked to pathological conditions (visceral obesity, insulin resistance, and non‐alcoholic fatty liver disease [NAFLD]) (Rada et al. 2020; Cifarelli et al. 2021). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.